Project Grant HT94252510193
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$703K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
This federal Project Grant award in the amount of $802,500.00 was issued by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant will fund preclinical gene therapy studies in a mouse model of TSC2 at Baylor College of Medicine in Houston, Texas. The award has a performance period from May 1, 2025 to April 30, 2028. The research aims to advance gene therapy approaches for treating tuberous sclerosis complex, a rare genetic...
The Department of the Army Medical Command awarded a $231,000 Project Grant to Research Institute At Nationwide Children's Hospital, with Nationwide Childrens Hospital as the parent organization, to support research into mechanisms underlying brain calcification in tuberous sclerosis complex from July 1, 2021 to June 30, 2023. The grant is part of the Military Medical Research and Development program, with the goal of transforming military and public health through innovative biomedical...
The Defense Health Agency awarded a $273,001 Project Grant to the Children's Research Institute through the Military Medical Research and Development program (CFDA 12.420) to support research on the treatment of epilepsy in tuberous sclerosis complex. The Children's Research Institute, operating under the parent organization Children's National Medical Center, will conduct research to investigate the transplantation of interneuron progenitors as a potential treatment for epilepsy associated...
This $713,818 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to characterize novel patient-specific modeling systems for NF2 disease research and therapeutic testing. The project will be conducted from September 1, 2024 through August 31, 2027. The Research Institute has extensive experience delivering federal research...
This $614,936 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a research project titled "The Clinical and Genetic Architecture of Autism Spectrum Disorder among Individuals with Tuberous Sclerosis Complex." The award, which spans the period from Jul 1, 2025 to Jun 30, 2028, will be performed by Baylor College of Medicine in Houston, Texas. This research aims to investigate the clinical and genetic...
The Project Grant award of $624,000 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program to the Research Institute at Nationwide Children's Hospital. The funding supports a project titled "SPLICING UP PD-L1 FOR IMMUNOTHERAPY ENHANCEMENT IN PEDIATRIC NEURONAL TUMORS" over a two-year period from September 30, 2023 to September 29, 2025. The goal is to conduct research to advance immunotherapy approaches...
The Children's Hospital Corporation, doing business as Boston Children's Hospital, was awarded a $796,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program.
The grant will fund research from July 2021 through June 2024 to investigate the contribution of rapamycin-insensitive processes to neurological symptoms in tuberous sclerosis complex. The Military Medical Research and Development program aims to advance biomedical...
The Defense Health Agency awarded a $1,249,009 Project Grant to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2023, funds a 4-year project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" to conduct medical research and development related to improving treatments for glioma, a type of brain cancer. As a non-profit research institute, the...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $148,942 to the Westfaelische Wilhelms-Universitaet Muenster in Germany to conduct research on identifying and characterizing the guanine nucleotide exchange factor (GEF) for the small GTPase Rheb as a novel target for treating tuberous sclerosis complex (TSC). The two-year award, running from July 1, 2024 to June 30, 2026, will support the university's...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and...